John P. Allen, Friedrich M. Wurst, Natasha Thon, Raye Z. Litten – 24 December 2012 – The accurate assessment of drinking by patients with alcoholic liver disease is important both before and after liver transplantation. Unfortunately, self‐reports by these individuals often underestimate their actual alcohol consumption. Several recently developed biochemical measures can provide additional information on a patient's use of alcohol.

Ahmed El‐Shamy, Michiko Shindo, Ikuo Shoji, Lin Deng, Tadao Okuno, Hak Hotta – 24 December 2012 – Hepatocellular carcinoma (HCC) is one of the common sequelae of hepatitis C virus (HCV) infection. It remains controversial, however, whether HCV itself plays a direct role in the development of HCC. Although HCV core, NS3, and NS5A proteins were reported to display tumorigenic activities in cell culture and experimental animal systems, their clinical impact on HCC development in humans is still unclear.

Manlio Vinciguerra – 22 December 2012

Giovanna Ferraioli, Raffaella Lissandrin, Carlo Filice – 22 December 2012

Mark J. Czaja – 22 December 2012

Homie Razavi, Antoine C. ElKhoury, Elamin Elbasha, Chris Estes, Ken Pasini, Thierry Poynard, Ritesh Kumar – 22 December 2012 – Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding of HCV disease progression and the associated cost can help the medical community manage HCV and develop treatment strategies in light of the emergence of several potent anti‐HCV therapies. A system dynamic model with 36 cohorts was used to provide maximum flexibility and improved forecasting.

Yoichi Hiasa, Hironori Ochi, Masashi Hirooka – 22 December 2012

Hiroyuki Tsuchiya, Kentaro Kogure, Goshi Shiota – 22 December 2012

Nadia Panera, Sara Ceccarelli, Cristiano Stefanis, Valerio Nobili, Anna Alisi – 22 December 2012

James E. Everhart, Elizabeth C. Wright – 19 December 2012 – Increased γ‐glutamyl transferase (GGT) activity is associated with liver injury and with mortality in the general population. Less is known about its association with chronic hepatitis C (HCV) outcomes. We examined GGT as a predictor of both virological response to treatment and long‐term clinical outcomes in the Hepatitis C Anti‐viral Treatment Against Cirrhosis Trial (HALT‐C).